tiprankstipranks
Inovio Pharmaceuticals (INO)
NASDAQ:INO
US Market
INO
Inovio Pharmaceuticals
RESEARCH TOOLSreports
Want to see INO full AI Analyst Report?

Inovio Pharmaceuticals (INO) Stock Forecast & Price Target

5,994 Followers
See the Price Targets and Ratings of:

INO Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Inovio
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

INO Stock 12 Month Forecast

Average Price Target

$4.50
▲(278.15% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Inovio Pharmaceuticals in the last 3 months. The average price target is $4.50 with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 278.15% change from the last price of $1.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.1,1.476923076923077,1.853846153846154,2.230769230769231,2.607692307692308,2.9846153846153847,3.361538461538462,3.738461538461539,4.115384615384616,4.492307692307692,4.86923076923077,5.246153846153847,5.623076923076924,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.1,1.3615384615384616,1.623076923076923,1.8846153846153848,2.1461538461538465,2.407692307692308,2.6692307692307695,2.930769230769231,3.1923076923076925,3.453846153846154,3.7153846153846155,3.976923076923077,4.238461538461539,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.1,1.2461538461538462,1.3923076923076922,1.5384615384615385,1.6846153846153846,1.8307692307692307,1.976923076923077,2.123076923076923,2.269230769230769,2.4153846153846152,2.5615384615384613,2.707692307692308,2.8538461538461535,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$6.00Average Price Target$4.50Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on INO
Edward Tenthoff
Piper Sandler
Piper Sandler
$6
Buy
404.20%
Upside
Reiterated
05/22/26
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)
H.C. Wainwright Analyst forecast on INO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$3
Hold
152.10%
Upside
Reiterated
03/16/26
Inovio Pharmaceuticals: Balancing INO-3107 Regulatory Uncertainty and Early-Stage Pipeline Potential Justifies Hold Rating and $3 Target
Oppenheimer Analyst forecast on INO
Hartaj Singh
Oppenheimer
Oppenheimer
$13
Buy
992.44%
Upside
Reiterated
11/11/25
Inovio Pharmaceuticals (INO) Receives a Buy from Oppenheimer
Jefferies Analyst forecast on INO
Roger Song
Jefferies
Jefferies
$2→$1.8
Buy
51.26%
Upside
Reiterated
08/13/25
Jefferies Sticks to Their Buy Rating for Inovio Pharmaceuticals (INO)
Citizens JMP Analyst forecast on INO
Roy Buchanan
Citizens JMP
Citizens JMP
$12
Buy
908.40%
Upside
Reiterated
08/13/25
Citizens JMP Sticks to Its Buy Rating for Inovio Pharmaceuticals (INO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on INO
Edward Tenthoff
Piper Sandler
Piper Sandler
$6
Buy
404.20%
Upside
Reiterated
05/22/26
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)
H.C. Wainwright Analyst forecast on INO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$3
Hold
152.10%
Upside
Reiterated
03/16/26
Inovio Pharmaceuticals: Balancing INO-3107 Regulatory Uncertainty and Early-Stage Pipeline Potential Justifies Hold Rating and $3 Target
Oppenheimer Analyst forecast on INO
Hartaj Singh
Oppenheimer
Oppenheimer
$13
Buy
992.44%
Upside
Reiterated
11/11/25
Inovio Pharmaceuticals (INO) Receives a Buy from Oppenheimer
Jefferies Analyst forecast on INO
Roger Song
Jefferies
Jefferies
$2→$1.8
Buy
51.26%
Upside
Reiterated
08/13/25
Jefferies Sticks to Their Buy Rating for Inovio Pharmaceuticals (INO)
Citizens JMP Analyst forecast on INO
Roy Buchanan
Citizens JMP
Citizens JMP
$12
Buy
908.40%
Upside
Reiterated
08/13/25
Citizens JMP Sticks to Its Buy Rating for Inovio Pharmaceuticals (INO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Inovio Pharmaceuticals

3 Months
Roy BuchananCitizens JMP
Success Rate
3/11 ratings generated profit
27%
Average Return
-14.24%
Copying Roy Buchanan's trades and holding each position for 3 Months would result in 27.27% of your transactions generating a profit, with an average return of -14.24% per trade.
1 Year
Roy BuchananCitizens JMP
Success Rate
0/11 ratings generated profit
0%
Average Return
-54.39%
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -54.39% per trade.
2 Years
Roy BuchananCitizens JMP
Success Rate
0/11 ratings generated profit
0%
Average Return
-60.90%
Copying Roy Buchanan's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -60.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INO Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
1
2
2
3
Buy
0
0
0
0
0
Hold
3
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
2
3
3
4
In the current month, INO has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. INO average Analyst price target in the past 3 months is 4.50.
Each month's total comprises the sum of three months' worth of ratings.

INO Financial Forecast

INO Earnings Forecast

Next quarter’s earnings estimate for INO is -$0.24 with a range of -$0.34 to -$0.14. The previous quarter’s EPS was -$0.28. INO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year INO has Performed in-line its overall industry.
Next quarter’s earnings estimate for INO is -$0.24 with a range of -$0.34 to -$0.14. The previous quarter’s EPS was -$0.28. INO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year INO has Performed in-line its overall industry.

INO Sales Forecast

Next quarter’s sales forecast for INO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. INO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year INO has Performed in-line its overall industry.
Next quarter’s sales forecast for INO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. INO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year INO has Performed in-line its overall industry.

INO Stock Forecast FAQ

What is INO’s average 12-month price target, according to analysts?
Based on analyst ratings, Inovio Pharmaceuticals’s 12-month average price target is 4.50.
    What is INO’s upside potential, based on the analysts’ average price target?
    Inovio Pharmaceuticals has 278.15% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is INO a Buy, Sell or Hold?
          Inovio Pharmaceuticals has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Inovio Pharmaceuticals’s price target?
            The average price target for Inovio Pharmaceuticals is 4.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $6.00 ,the lowest forecast is $3.00. The average price target represents 278.15% Increase from the current price of $1.19.
              What do analysts say about Inovio Pharmaceuticals?
              Inovio Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of INO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.